Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models
F.Ghiringhelli et al, J Clin Oncol, 2023
(suppl 16; abstr e14661) 10.1200/JCO.2023.41.16_suppl.e14661 Link to Abstract
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
